The ICON Study: Outcomes After FMT for Patients With IBD and CDI

Inclusion Criteria: * Adults age 18 or greater * Confirmed recurrent CDI by positive PCR or EIA toxin test defined at ≥ 2 episodes and vancomycin failure within one year with the most recent being within the past 3 months. * Confirmed diagnosis of IBD with colonic involvement (ulcerative colitis, Crohn's colitis or ileocolitis or indeterminate colitis) for ≥ 3 months * Undergoing FMT via colonoscopy for CDI as part of standard medical care Exclusion Criteria: * Unable or unwilling to undergo a colonoscopy * Inpatient status * Anticipated immediate or upcoming surgery within 30 days * Need for continued non-anti-CDI antibiotic therapy * History of total or subtotal proctocolectomy * Isolated ileal or small bowel disease * Pregnancy or lactation * Female patients who are pregnant or breastfeeding or plan to become pregnant in the next 6 months. * Patients who are unable to give informed consent * Participation in a clinical trial in the preceding 30 days or simultaneously during this trial * Severe food allergy (anaphylaxis or anaphylactoid-like reaction) * Life expectancy \< 6 months * Unable to adhere to protocol requirements * Any condition that the physician investigators deems unsafe, including other conditions or medications that the investigator determines that it will put the subject at greater risk from FMT * Known concurrent HIV, Hepatitis B or C infection * Concurrent PSC * Patients with WBC\< 3.0 x109th/L at baseline * Patients with platelet count \< 100 x109th/L * Patients with initial elevation of AST or ALT \> 1.5 times above normal limit at baseline * Non - steroidal anti-inflammatory medications (NSAIDs) as long-term treatment, defined as use for at least 4 days a week each month * Treatment with vancomycin or metronidazole for more then 60 days prior to enrollment